NCT05395533View on ClinicalTrials.gov

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.

Trial Locations (6)

100021

Chinese Academy of Medical Sciences, Cancer Hospital, Beijing

215000

Second Affiliated Hospital of Soochow University, Suzhou

300000

Tianjin Medical University Cancer Institute & Hospital (TMUCIH), Tianjin

450000

Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510000

Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou

All Listed Sponsors
lead

Zhejiang Teruisi Pharmaceutical Inc.

INDUSTRY

NCT05395533 - A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. | Biotech Hunter | Biotech Hunter